US-based Cancer Genetics (CGI) has collaborated with the Indian Cooperative Oncology Network (ICON) to minimise cancer mortality rates by optimising clinical outcomes for patients in India.
The firms will jointly develop educational and clinical research activities to boost the use of advanced technology in clinical testing and trials for oncology.
ICON promotes clinical research for the development of techniques to prevent and manage the disease.
According to CGI, ICON is strategically positioned for the evaluation of new developments in precision oncology and its impact on oncologists and patients in the country.
The partnership is intended to enable the oncology network to further analyse the targeted therapies that could be provided along with better genomic insights on tumours.
It is expected that the collaborative approach will allow new recommendations for optimal use of molecular assays in the country.
The firms intend to utilise their complementary expertise to train Indian oncologists and provide them with advanced technology.
CGI’s India lab, CG India, is set to offer comprehensive scientific capacity, resources and new clinical diagnostic tests to the oncologists.
Cancer Genetics president and CEO Panna Sharma said: “There is a severe shortage of properly trained physicians, with only 2,000 specialised oncologists to treat the vast number of patients.
“This discrepancy, along with the country’s growing economy, population, and demand for better medicines encourages partnerships with Western companies to improve patient care in India; thereby opening up a huge market with high unmet medical need.
“With extensive experience in diagnostic assays and services, various biopharma partnerships and a comprehensive test menu, CGI offers valuable resources to the Indian oncology community to optimise the care and outcomes of Indian cancer patients.”